Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.70 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.70 |
| ▸ | KMO | O15229 | 2/20 | 0.67 |
| ▸ | UNG | P13051 | 1/20 | 0.65 |
| ▸ | ERN1 | O75460 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 2/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12212910 | 1.00 | TRIM24 (0.70) | TRIM24TRIM33KMOUNGERN1 | |
| SCHEMBL29955830 | 1.00 | TRIM24 (0.70) | TRIM24TRIM33KMOUNGERN1 | |
| SCHEMBL29952036 | 0.87 | UNG (0.79) | TRIM24TRIM33KMOUNGERN1 | |
| SCHEMBL2587878 | 0.87 | UNG (0.79) | TRIM24TRIM33KMOUNGERN1 | |
| SCHEMBL29577419 | 0.87 | KMO (0.87) | TRIM24TRIM33KMOERN1GAA | |
| SCHEMBL14683877 | 0.87 | KMO (0.87) | TRIM24TRIM33KMOERN1GAA | |
| SCHEMBL3220396 | 0.85 | KMO (0.91) | TRIM24TRIM33KMOERN1GAA | |
| SCHEMBL437537 | 0.84 | KMO (0.91) | KMOERN1GAALMNARXRA | |
| SCHEMBL1676039 | 0.84 | KMO (0.65) | TRIM24TRIM33KMOUNGERN1 | |
| SCHEMBL1348028 | 0.84 | ERN1 (0.65) | TRIM24TRIM33KMOERN1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287230-B2 | Selective aerobic oxidation of dimethylbiphenyls | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180179141-A1 | SELECTIVE AEROBIC OXIDATION OF DIMETHYLBIPHENYLS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2018-06-28 | — | — | US | disclosed |
| WO-2017018751-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | 동국대학교 산학협력단 | 2017-02-02 | — | — | WO | disclosed |
| US-9045750-B2 | Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 | MA YUELONG (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | MA YUELOG (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| EP-2503890-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124802-B2 | e.g. N-methyl-N-propargyl-4-hydroxybenzyl amine; monoamine oxidase inhibitors; are mediated via a peripheral (i.e., non-CNS) mechanism; antidiabetic agent, metabolic disordes, obesity, insulin resistance | JENRIN DISCOVERY, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | IMMUSOL INCORPORATED (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008092091-A2 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008092091-A2 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2008-07-31 | — | — | US | disclosed |
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | disclosed |
| EP-1309575-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | Galderma Research & Development (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012210-A9 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002012210-A1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, COASY | TRIM24 2472/4885TRIM33 2280/4885KMO 1964/4885 |
| US-20080182824-A1 | MAO INHIBITING N-BENZYL-N-PROPARGYL-AMINES USEFUL FOR TREATING OBESITY | MAOA, MAOB, PNMT | TRIM24 3200/4885TRIM33 3512/4885KMO 56/4885 |
| US-20180179141-A1 | SELECTIVE AEROBIC OXIDATION OF DIMETHYLBIPHENYLS | CYP1B1, MSMO1, CYP1A1 | TRIM24 951/4885TRIM33 1353/4885KMO 84/4885 |
| US-10287230-B2 | Selective aerobic oxidation of dimethylbiphenyls | CYP1B1, MSMO1, CYP1A1 | TRIM24 951/4885TRIM33 1353/4885KMO 84/4885 |
| US-20130052731-A1 | HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 | AGO2, HNRNPH3, HCLS1 | TRIM24 1951/4885TRIM33 179/4885KMO 4452/4885 |
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | NQO2, MCL1, KRAS | TRIM24 2880/4885TRIM33 2594/4885KMO 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.